Strategic partnerships Opportunity to deepen collaboration with Bostwick Laboratories through joint marketing and genomic integration, leveraging the existing GenomeDx partnership to expand to additional tumor types and testing panels for urologic, dermatology, gastroenterology, gynecology, nephrology, and hematology pathology services.

Clinical expansion Target growth by offering advanced molecular diagnostics, Decipher-like classifiers, and integration of genomic insights into pathology workflows to enhance diagnostic accuracy and personalized treatment plans for cancer patients.

Market positioning Position as a specialized pathology provider with a leadership stance in urologic pathology and a broad footprint across multiple subspecialties, appealing to mid-sized hospitals and health systems seeking high-quality, consolidated lab services.

Financial alignment With a revenue range of 50–100 million and a mid-sized employee base, propose scalable service agreements, bundled testing menus, and value-based pricing pilots tailored to mid-market health networks and regional hospitals.

Technology enablement Leverage existing tech stack to streamline pathology workflows and reporting; offer integrated IT and data analytics support, secure data exchange, and analytics-driven insights to enhance turnaround times and diagnostic confidence.